Autolus Therapeutics (NASDAQ:AUTL) Given “Buy” Rating at Needham & Company LLC

Needham & Company LLC restated their buy rating on shares of Autolus Therapeutics (NASDAQ:AUTL) in a research report report published on Thursday,Benzinga reports. The brokerage currently has a $10.00 price target on the stock.

Several other equities analysts have also commented on AUTL. Mizuho lowered their price target on shares of Autolus Therapeutics from $12.00 to $10.00 and set an “outperform” rating for the company in a research report on Tuesday, March 31st. Truist Financial upgraded shares of Autolus Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 25th. HC Wainwright started coverage on shares of Autolus Therapeutics in a research report on Tuesday, February 17th. They set a “buy” rating and a $9.00 price target for the company. Zacks Research upgraded shares of Autolus Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Friday, March 13th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Autolus Therapeutics in a research report on Wednesday, January 21st. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $8.50.

Autolus Therapeutics Stock Performance

Shares of NASDAQ:AUTL opened at $1.47 on Thursday. The stock has a market capitalization of $391.23 million, a price-to-earnings ratio of -1.36 and a beta of 2.04. Autolus Therapeutics has a 1-year low of $1.11 and a 1-year high of $2.70. The company’s fifty day moving average is $1.48 and its two-hundred day moving average is $1.52.

Autolus Therapeutics (NASDAQ:AUTL) last released its quarterly earnings results on Friday, March 27th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.07). The firm had revenue of $24.29 million for the quarter, compared to the consensus estimate of $23.92 million. Autolus Therapeutics had a negative return on equity of 99.05% and a negative net margin of 381.40%. Sell-side analysts expect that Autolus Therapeutics will post -0.94 EPS for the current fiscal year.

Hedge Funds Weigh In On Autolus Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Invesco Ltd. boosted its position in shares of Autolus Therapeutics by 53.3% during the 1st quarter. Invesco Ltd. now owns 32,738 shares of the company’s stock valued at $51,000 after purchasing an additional 11,381 shares in the last quarter. Jane Street Group LLC boosted its position in shares of Autolus Therapeutics by 809.4% during the 1st quarter. Jane Street Group LLC now owns 102,493 shares of the company’s stock valued at $159,000 after purchasing an additional 91,222 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Autolus Therapeutics by 90.5% during the 2nd quarter. Geode Capital Management LLC now owns 164,314 shares of the company’s stock valued at $375,000 after purchasing an additional 78,058 shares in the last quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in shares of Autolus Therapeutics during the 2nd quarter valued at about $1,288,000. Finally, The Manufacturers Life Insurance Company boosted its position in shares of Autolus Therapeutics by 41.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 38,419 shares of the company’s stock valued at $88,000 after purchasing an additional 11,289 shares in the last quarter. Institutional investors own 72.83% of the company’s stock.

About Autolus Therapeutics

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.